NANOBIOTIX SA - ADR
NBTXNASDAQTrading Snapshot
- Day Range
- $31.49 – $32.20
- 52-Week Range
- $14.78 – $57.14
- Volume
- $2.25B
- Avg Volume
- $2.90B
- Shares Outstanding
- 50.6M
- Next Earnings
- Nov 6, 2026
Fundamentals Snapshot
- Annual Revenue
- $30M
- Last Q Revenue
- $4M
- P/E Ratio
- -25.3
- P/S Ratio
- 213.1x
- EPS (TTM)
- $-1.08
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +1.2%
Why Investors Own NBTX
- ✓High-growth profile — revenue up +23.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 50% gross margin and 8% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
NANOBIOTIX SA - ADR
NBTX
StockOtter · stockotter.spaceAbout NANOBIOTIX SA - ADR
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
NANOBIOTIX Provides First Half 2026 Operational and Financial Update
PARIS and CAMBRIDGE, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treat
Voting Rights and Shares Capital of the Company
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Receives Average Recommendation of “Moderate Buy” from Analysts
Shares of Nanobiotix S.A. - Sponsored ADR (NASDAQ: NBTX - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the six brokerages that are presently covering the company, Marketbeat repor
NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer
All 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the injection procedure, and intratumoral injection was deemed feasible One-year
NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
PARIS and CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatme